Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 26;10(1):173.
doi: 10.1038/s41392-025-02260-5.

De novo induction of tertiary lymphoid structures: an immunotherapeutic strategy in pancreatic cancer

Affiliations

De novo induction of tertiary lymphoid structures: an immunotherapeutic strategy in pancreatic cancer

Azaz Ahmed et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Overview with central proposed elements of tertiary lymphoid structure (TLS) lymphoneogenesis in mouse models. IL-33 produced in the gut of PDAC-bearing mice leads to migration of KLRG1+ ILC2 cells towards the tumor and interaction with CD11b+ myeloid helper cells. This in turn attracts B cells (and T cells) to form TLSs (as shown in the schematic pixelated TLS representation). The induction of TLSs was recapitulated in mice treated with the human drug candidate H-rIL-33

References

    1. Amisaki, M. et al. IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer. Nature638, 1076–1084 (2025). - PMC - PubMed
    1. Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin.75, 10–45 (2025). - PMC - PubMed
    1. Vanhersecke, L. et al. Standardized pathology screening of mature tertiary lymphoid structures in cancers. Lab Investig.103, 100063 (2023). - PubMed
    1. Ahmed, A. et al. Tertiary lymphoid structures and their association to immune phenotypes and circulatory IL2 levels in pancreatic ductal adenocarcinoma. Oncoimmunology11, 2027148 (2022). - PMC - PubMed
    1. Italiano, A. et al. Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. Nat. Med.28, 1199–1206 (2022). - PubMed

LinkOut - more resources